226388-60-9

Basic information

• Product Name: 4-[4-(Phenylsulfanyl)phenylsulfonyl]-1-(2-propynyl)piperidine-4-carbohydroxamic acid hydrochloride
• Synonyms: SC-276
• CAS NO: 226388-60-9
• Molecular Formula: C₂₁H₂₃ClN₂O₄S₂
• Molecular Weight: 467.00946
• Mol File: 226388-60-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-[4-(Phenylsulfanyl)phenylsulfonyl]-1-(2-propynyl)piperidine-4-carbohydroxamic acid hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(Phenylsulfanyl)phenylsulfonyl]-1-(2-propynyl)piperidine-4-carbohydroxamic acid hydrochloride(226388-60-9)
• EPA Substance Registry System: 4-[4-(Phenylsulfanyl)phenylsulfonyl]-1-(2-propynyl)piperidine-4-carbohydroxamic acid hydrochloride(226388-60-9)

Safety Data

• Hazardous Substances Data: 226388-60-9(Hazardous Substances Data)

Upstream product

• 226396-65-2 4-(4-phenylsulfanyl-benzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic acid ethyl ester 
• 226396-66-3 4-(4-phenylsulfanyl-benzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic acid 
• 226396-67-4 4-(4-phenylsulfanyl-benzenesulfonyl)-1-prop-2-ynyl-piperidine-4-carboxylic acid (tetrahydro-pyran-2-yloxy)-amide 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 405-31-2 bis(4-fluorophenyl)disulfide 
• 226396-63-0 1-(tert-butyl) 4-ethyl 4-[(4-fluorophenyl)sulfonyl]piperidine-1,4-dicarboxylate 
• 226396-64-1 4-(4-fluorobenzenesulfonyl)-1-prop-2-ynylpiperidine-4-carboxylic acid ethyl ester 
• 226396-62-9 1-tert-butyl 4-ethyl 4-[(4-fluorophenyl)thio]piperidine-1,4-dicarboxylate 

Relevant articles and documents

Synthesis and structure-activity relationships of β- and α-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors with oral antitumor efficacy

α-Piperidine-β-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the β-sulfones subsequently led to the discovery of hitherto unknown α-sulfone h

Aromatic sulfone hydroxamic acid metalloprotease inhibitor

A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor. A contemplated compound corresponds in structure to formula B, below,